COMPARE · Data as of August 28, 2026
LTC vs NHI
Verdict: Side-by-side breakdown using the Bull Rankings model. LTC scored 76.0, NHI scored 74.0 — LTC leads.
Compare another set
Different reporting periods. LTC's fundamentals are as of June 2026, but NHI's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
LTC
LTC Properties, Inc.
78Fin
$40.53 · $2.2B
fundamentals as of
Strength gap
5.2
LTC leads
NHI
National Health Investors, Inc.
72.8Fin
$72.03 · $3.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthLTC+25.3%
- Strongest balance sheetLTC0.85
Side by side · every name on one set of axes
Fundamentals, head-to-head
LTC
NHI
5.6%A-
Yield
5.2%A-
+25.3%A-
Rev
+12.1%B+
0.85B+
D/E
0.98B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
LTCLTC Properties, Inc.
Why now
REIT - Healthcare Facilities · market cap $2.2b. 6% off the 52-week high of $43.00. Revenue growing +25% — in hypergrowth territory. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $42.29 (implying +4% upside).
Moat
Net margin 40% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Dividend payout 81% of earnings on a 5.6% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
NHINational Health Investors, Inc.
Why now
REIT - Healthcare Facilities · market cap $3.5b. Down 21% from 52-week high of $91.38 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $82.13 (implying +14% upside).
Moat
Net margin 38% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Dividend payout 106% of earnings on a 5.2% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.